InvestorsObserver
Sign Up Login

FNCH Finch Therapeutics Group Inc

$2.22 $0.00 (0.00%)
Add to Watchlist Compare
Overall

FNCH Stock Analysis Overview

What this means: InvestorsObserver gives Finch Therapeutics Group Inc (FNCH) an overall rank of 34, which is below average. Finch Therapeutics Group Inc is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 34 means that 66% of stocks appear more favorable to our system.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

View Sample Report
Fundamental PREMIUM

FNCH Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

Short-Term Technical PREMIUM

FNCH Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

Long-Term Technical PREMIUM

FNCH Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

Analyst Ranking PREMIUM

FNCH Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

Valuation PREMIUM

FNCH Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

Stock Sentiment PREMIUM

FNCH Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

FNCH Stock Analysis Overview

What this means: InvestorsObserver gives Finch Therapeutics Group Inc (FNCH) an overall rank of 34, which is below average. Finch Therapeutics Group Inc is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 34 means that 66% of stocks appear more favorable to our system.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full FNCH report

FNCH Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

FNCH Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

FNCH Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

FNCH Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

FNCH Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

FNCH Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

Finch Therapeutics Group Inc (FNCH) Analyst Forecast

FNCH Price, Volume, Earnings, and Dividend Date

  • Last Price $2.22
  • Previous Close $2.22
  • Change $0.00
  • Open $2.30
  • Volume 252,100
  • Avg. Volume (100-day) 606,943
  • Market Cap 105,581,198
  • Days Range 2 - 2.3
  • 52-week Range 1.71 - 22.1
  • Dividend Yield —
  • Ex. Dividend Date —
  • P-E —
  • EPS —
  • Earnings Date 08/14/22
  • Sector Healthcare
  • Industry Biotechnology
  • Avg. Analyst Rec. Premium
  • Beta 0.294
  • PEG Ratio —

Finch Therapeutics Group Inc (FNCH) Company Description

Finch Therapeutics Group Inc is a clinical-stage microbiome therapeutics company. It is leveraging Human-First Discovery platform to develop a novel class of orally administered biological drugs. It is developing novel therapeutics to deliver missing microbes and their clinically relevant biochemical functions to correct dysbiosis and the diseases that emerge from it. The lead product candidate is CP101 which delivers a complete microbiome and is being developed initially for the treatment of patients with recurrent Clostridioides difficile infection.

Finch Therapeutics Group Inc (FNCH) Stock Chart

View Interactive FNCH chart

My Watchlists

Follow Your Favorite Stocks

Top Stocks in Biotechnology

Company Price
Veru Inc (VERU) (VERU) $15.01
SC Pharmaceuticals Inc (SCPH) (SCPH) $4.80
Trevi Therapeutics Inc (TRVI) (TRVI) $2.24
Vaxcyte Inc (PCVX) (PCVX) $24.03
Fennec Pharmaceuticals Inc (FENC) (FENC) $5.97
Adma Biologics (ADMA) (ADMA) $2.01
Foghorn Therapeutics Inc (FHTX) (FHTX) $11.60
Concert Pharmaceutic (CNCE) (CNCE) $4.79
Bellus Health Inc (BLU) (BLU) $8.80
Crinetics Pharmaceuticals Inc (CRNX) (CRNX) $19.91